Professor | 黄敏 | 数字化转型顾问

Name

黄敏

Contact Information

mhuang@simm.ac.cn

Language ability

中文, 英语

Province

上海

University/Lab Affiliation and Title	中国科学院大学
Faculty	Medical School
Academic Background & Achievements	2002-09--2007-06 博士: 中国科学院上海药物研究所 1998-09--2002-06 本科: 中国药科大学
Work Experience	2013-01~现在 - 中国科学院上海药物研究所 - 研究员 2011-10~2012-12 - 中国科学院上海药物研究所 - 副研究员 2011-03~2011-09 - 中国科学院上海药物研究所 - 助理研究员 2008-01~2011-02 - 美国哈佛医学院Dana-Farber肿瘤研究所 - 博士后
Awards	中国青年女科学家奖 (2023): 国家级药明康德生命化学研究奖 (2017): 其他上海市科技系统青年五四奖章 (2017): 省级上海市巾帼创新新秀奖暨上海市“三八红旗手” (2016): 省级施维雅青年药理学家奖 (2016): 其他中源协和生命医学奖创新突破奖 (2016): 其他中国科学院卢嘉锡青年人才奖 (2013): 部委级

University/Lab Affiliation and Title

中国科学院大学

Faculty

Medical School

Academic Background & Achievements

Work Experience

Awards

Areas of Focus	肿瘤药理学肿瘤代谢肿瘤免疫
Publications	Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer, 黄敏, 2024 Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, 黄敏, 2023 Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, 黄敏, 2022 Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, 黄敏, 2022 NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, 黄敏, 2022 Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, 黄敏, 2022 SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, 黄敏, 2022 Antitumor pharmacological research in the era of personalized medicine, 黄敏, 2022 Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, 黄敏, 2022 Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, 黄敏, 2022

Areas of Focus

肿瘤药理学
肿瘤代谢
肿瘤免疫

Publications

Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer, 黄敏, 2024
Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, 黄敏, 2023
Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, 黄敏, 2022
Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, 黄敏, 2022
NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, 黄敏, 2022
Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, 黄敏, 2022
SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, 黄敏, 2022
Antitumor pharmacological research in the era of personalized medicine, 黄敏, 2022
Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, 黄敏, 2022
Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, 黄敏, 2022

癌症药理学代谢免疫学治疗研究药物开发肿瘤学生物标志物临床试验

曹丽伟 - 南方科技大学

Area of Focus
蛋白质组学 | 方法开发 | 技术创新 | 生物问题 | 人类疾病 | 治疗 | 应用 | 研究 | 科学 | 医学

韩超珊 - 南方科技大学

刘嘉玲 - 南方科技大学

View All

Personal Information